Answer
Carfilzomib (Kyprolis) should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus, as it can cause foetal harm; patients exposed during pregnancy should be informed of the potential foetal hazard.
Sources for this answer
- KyprolisAmgen Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 21Document updated
Sources checked